Vol. 22/No. 20

Although there has been dramatic progress in the treatment landscape for metastatic melanoma over the past decade, many patients whose tumors harbor NRAS mutations have not shared in the improved outcomes.

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

Investigators look to boost systemic therapy options for patients with malignant pleural mesothelioma with the phase 3 DREAM3R trial.

Since Charu Aggarwal, MD, MPH, helped conduct the first phase 1 trial of pembrolizumab nearly a decade ago, she has been recognized as a pioneer in testing immunotherapy treatments for thoracic cancers.

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Alexander J. Stratigos, MD, PhD, discussed the effect cemiplimab will have on the treatment landscape of patients with advanced BCC.

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Maurie Markman, MD, highlights the ongoing regulatory concerns that demand attention of the FDA in the cancer arena amidst evolving issues regarding COVID-19.